Ridinilazole + Vancomycin
Phase 3Completed 1 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Clostridioides Difficile Infection
Conditions
Clostridioides Difficile Infection
Trial Timeline
Jan 28, 2019 → Nov 17, 2021
NCT ID
NCT03595553About Ridinilazole + Vancomycin
Ridinilazole + Vancomycin is a phase 3 stage product being developed by Summit Therapeutics for Clostridioides Difficile Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT03595553. Target conditions include Clostridioides Difficile Infection.
What happened to similar drugs?
0 of 3 similar drugs in Clostridioides Difficile Infection were approved
Approved (0) Terminated (1) Active (2)
Hype Score Breakdown
Clinical
17
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04802837 | Phase 3 | Terminated |
| NCT03595553 | Phase 3 | Completed |
Competing Products
7 competing products in Clostridioides Difficile Infection
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD5148 | AstraZeneca | Phase 2 | 42 |
| AZD5148 + Placebo | AstraZeneca | Phase 1 | 29 |
| C.difficile vaccine | Pfizer | Phase 3 | 47 |
| Ridinilazole + Vancomycin | Summit Therapeutics | Phase 3 | 29 |
| REC-3964 | Recursion Pharmaceuticals | Phase 2 | 21 |
| SER-109 | Seres Therapeutics | Pre-clinical | 16 |
| SER-109 | Seres Therapeutics | Phase 3 | 30 |